Estrella Immunopharma, Inc.
ESLA
$0.96
-$0.0095-0.98%
NASDAQ
| 06/30/2025 | 03/31/2025 | 09/30/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 108.22% | 56.15% | -60.30% | -60.30% | 172.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.38% | 348.20% | 80.52% | 80.52% | 44.59% |
| Operating Income | -40.38% | -348.20% | -80.52% | -80.52% | -44.59% |
| Income Before Tax | -40.38% | -348.20% | -80.52% | -80.52% | -44.59% |
| Income Tax Expenses | -43.75% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.34% | -348.20% | -80.52% | -80.52% | -44.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.34% | -348.20% | -80.52% | -80.52% | -44.65% |
| EBIT | -40.38% | -348.20% | -80.52% | -80.52% | -44.59% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -41.16% | -340.15% | 94.75% | 94.75% | 97.64% |
| Normalized Basic EPS | -41.09% | -337.35% | 94.75% | 94.75% | 97.64% |
| EPS Diluted | -41.16% | -340.15% | 94.75% | 94.75% | 97.64% |
| Normalized Diluted EPS | -41.09% | -337.35% | 94.75% | 94.75% | 97.64% |
| Average Basic Shares Outstanding | -0.58% | 1.88% | 3,339.58% | 3,339.58% | 6,028.15% |
| Average Diluted Shares Outstanding | -0.58% | 1.88% | 3,339.58% | 3,339.58% | 6,028.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |